Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab + adalimumab for severe or critical COVID-19
ChiCTR2000030580Phase 4Recruiting
- Sponsor
- Shanghai General Hospital
- Start
- Feb 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of tocilizumab and adalimumab in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Shanghai General Hospital. Primary endpoints: Chest computerized tomography, Nucleic acid detection of novel coronavirus and 3 more. Started Feb 2020; status: recruiting.
02
Drugs
tocilizumabadalimumab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2000030580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000030580.